Natural products as leads to anticancer drugs

Clinical and Translational Oncology

Volumn 9, Issue 12, 2007, Pages 767-776

  Gordaliza, M ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Anticancer; Camptothecin; Natural lead compound; Podophyllotoxin; Taxol; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CAMPTOTHECIN; CISPLATIN; CURCUMIN; DOCETAXEL; ECO 4601; ETOPOFOS; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; IRINOTECAN; IXABEPILONE; METHOTREXATE; NATURAL PRODUCT; OXALIPLATIN; PACLITAXEL; PODOPHYLLOTOXIN; ROMIDEPSIN; TENIPOSIDE; TOPOTECAN; VINBLASTINE; VINCRISTINE; BIOLOGICAL PRODUCT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DNA MODIFICATION; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HODGKIN DISEASE; HOMEOPATHY; HUMAN; HYBRIDIZATION; LUNG CANCER; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; RHEUMATOID ARTHRITIS; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG SCREENING; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS;

EID: 39149098194     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0138-9     Document Type: Article

References (159)

1. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477
2. Wilson RM, Danishefsky SJ (2006) Small molecule natural products in the discovery of therapeutic agents: The synthesis connection. J Org Chem 71:8329-8351
3. Wilson RM, Danishefsky SJ (2007) Applications of total synthesis toward the discovery of clinically useful anticancer agents. Chem Soc Rev 36:1207-1226
4. Mukherjee AK, Basu S, Sarkat N, Ghosh AC (2001) Advances in cancer therapy with plant based natural products. Curr Med Chem 8:1467-1486
5. Lee KH (1999) Novel antitumor agents from higher plants. Med Res Rev 19:569-596
6. Paterson I, Anderson EA (2005) The renaissance of natural products as drug candidates. Science 310:451-453
7. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206-220
8. Lee K-H (2004) Current developments in discovery and design of new drug candidates from plant natural. J Nat Prod 67:273-283
9. Butler MS (2005) Natural products to drugs: Natural products derived compounds in clinical trials. Nat Prod Rep 22:162-195
10. Butler MS (2004) The role of the natural product chemistry in drug discovery. J Nat Prod 67:2141-2153
11. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206-220
12. Newman DJ, Cragg GM (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67:1216-1238
13. Hamann MT, Hill R, Roggo S (2007) Marine natural products. Key advances to the practical application of this resource in drug development. Chimia 61:313-321
14. Simmons TL, Andrianasolo E, McPhail K et al (2005) Marine natural products as anticancer drugs. Mol Cancer Ther 4:333-342
15. Marris E (2006) Marine natural products: Drugs from the deep. Nature 443:904-905
16. Schwartsmann G, Brondani da Rocha A, Mattei J, Martins Lopes R (2003) Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs 12:1367-1383
17. Blunt JW, Copp BR, Hu VP et al (2007) Marine natural products. Nat Prod Rep 24:31-86
18. Blunt JW, Copp BR, Munro MHG et al (2006) Marine natural product. Nat Prod Rep 23:26-78
19. Morris JC, Nicholas GM, Phillips AJ (2007) Marine natural products: synthetic aspects. Nat Prod Rep 24:87-108
20. Newman DJ, Cragg GM, Sanader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66:1022-1037
21. Glaser KB (2007) HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol 74:659-671
22. Bayes M, Rabasseda X, Prous JR (2007) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 29:303-311
23. Mosley CA, Liotta DC, Snyder JP (2007) Highly active anticancer curcumin analogues. Adv Exp Med Biol 595:77-103
24. Youssef D, Nichols CE, Cameron TS et al (2007) Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett 17:5624-5629
25. Johnson JJ, Mukhtar H (2007) Curcumin for chemoprevention of colon cancer. Cancer Lett 255:170-181
26. Cao J, Liu T, Jia L et al (2007) Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic Biol Med 43:968-975
27. Shishodia S, Chaturvedi MM, Aggarwal BB (2007) Role of curcumin in cancer therapy. Curr Prob Cancer 31:243-305
28. Clardy J (2004) Lessons from natural molecules. Nature 432:829-837
29. Hill RA, Sutherland A (2007) Hot off the press. Nat Prod Rep 24:14-17
30. Amagata T, Minoura K, Numata A (2006) Gymnastatins F-H, cytostatic metabolites from the sponge-derived fungus Gymnascella dankaliensis. J Nat Prod 86:1384-1388
31. Ge HM, Xu C, Wang XT et al (2006) Hopeanol: A potent cytotoxin with a novel skeleton from Hopea exalata. Eur J Org Chem 71:5551-5554
32. Mentel M, Breinbauer R (2007) Combinatorial solid-phase natural product chemistry. Topics Curr Chem 278:209-241
33. Füllbeck M, Michalsky E, Dunkel M, Preissner R (2006) Natural products: Sources and data bases. Nat Prod Rep 23:347-356
34. Kingston DGI, Newman DJ (2005) The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries. Curr Opin Drug Discov Dev 8:207-227
35. Baltz R (2006) Combinatorial biosynthesis of novel antibiotics and other secondary metabolites in actinomycetes. SIM News 56:148-158
36. Nisbet LJ, Moore M (1997) Will natural products remain an important source of drug research for the future? Curr Opin Biotechnol 8: 708-712
37. Ayres DC, Loike JD (1990) Lignans. Chemical, biological and clinical properties. Cambridge University Press, Cambridge
38. Harwelln JL, Schrecker AW (1951) Components of podophyllin. V. The constitution of podophyllotoxin. J Am Chem Soc 73:2909-2916
39. Beutner KR (1996) Podophyllotoxin in the treatment of genital warts. Curr Probl Dermatol 24:227-232
40. Sudo K, Konno K, Shigeta S, Yokota T (1998) Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication. Antivir Chem Chemother 9:263-267
41. Leander K, Rosen B (1988) Medicinal used for podophyllotoxin. US patent 4,788,216
42. Ahlmen M, Ahlmen J, Svalander C, Bucht H (1987) Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 6:27-38
43. Pugh NI, Khan I, Moraes RM, Pasco D (2001) Podophyllotoxin lignans enhance IL-1E but suppress TNF-a mRNA expression in LPS-treated monocytes. Immunopharmacol Immunotoxicol 23:83-95
44. Subrahmanyam D, Renuka B, Rao CV et al (1998) Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents. Bioorg Med Chem Lett 8:1391-1396
45. Utsugi T, Shibata J, Sugimoto Y et al (1996) Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 56:2809-2814
46. Fisher RI, Gaynor ER, Dahlberg S et al (1994) A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 5[Suppl 2]:91-95
47. Damayanthi Y, Lown JW (1998) Podophyllotoxins: Current status and recent developments. Curr Med Chem 5:205-252
48. Imbert TF (1998) Discovery of podophyllotoxins. Biochimie 80:207-222
49. Buss AD, Waigh RD (1995) In: Wolff ME (ed.) Natural products as leads for new pharmaceuticals. John Wiley & Sons Inc, New York, Chapter 24
50. Gordaliza M, García PA, Miguel del Corral JM et al (2004) Podophyllotoxin: Distribution, sources, applications and new cytotoxic derivatives. Toxicon 44:441-459
51. Gordaliza M, Castro A, Miguel del Corral JM, San Feliciano A (2000) Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Design 6:1811-1839
52. Gordaliza M, Miguel del Corral JM, Castro MA et al (1995) Synthesis and evaluation of pyrazolignans. A new class of cytotoxic agents. Bioorg Med Chem 3:1203-1210
53. Von Wartburg A, Stähelin H (1993) Etoposide. In: Lednicer D (ed.) Chronicles of drug discovery. American Chemical Society, Washington DC, pp 349-380
54. Fleming RA, Miller AA, Steward CF (1989) Etoposide: An update. Clin Pharm 8:274-293
55. Meresse P, Dechaux E, Monneret C, Bertounesque E (2004) Etoposide: discovery and medicinal chemistry. Curr Med Chem 11: 2443-2466
56. Stahelin H, Von Wartburg A (1989) From podophyllotoxin glucoside to etoposide. Progress Drug Res 33:169-266
57. Srivastava V, Negi AS, Kumaar JK et al (2005) Plant-based anticancer molecules: A chemical and biological profile of some important leads. Bioorg Med Chem 13:5892-5908
58. Jardin I (1980) Podophyllotoxins. In: Cassady JM, Douros JD (eds) Anticancer agents based on natural models. Academic Press, New York, pp 319-351
59. Gertsch J, Meier S, Tschopp N, Altmann K-H (2007) New tubulin inhibitors from plants a critical assessment. Chimia 61:368-372
60. Hait WN, Rubin E, Alli E, Goodin S (2007) Tubulin targeting agents. Update Cancer Therapeutics 2:1-18
61. Jordan MA, Wilson L (2004) Microtubules as target for anticancer drugs. Nat Rev Cancer 4: 253-265
62. Massanet GM, Pando E, Rodríguez-Luis F, Zubia E (1989) Lignans: A review. Fitoterapia 60: 3-35
63. Row R (1978) Chemistry of lignans. Andhra University Press, Waltair, India
64. Ward RS (1997) Lignans, neolignans, and related compounds. Nat Prod Rep 14:43-74
65. Whiting DA (1990) Lignans, neolignans, and related compounds. Nat Prod Rep 7:349-364
66. Canel C, Moraes RM, Dayan FE, Ferreira D (2000) Molecules of interest: podophyllotoxin. Phytochemistry 54:115-120
67. Botta B, Delle Monache G, Misiti D et al (2001) Aryltetralin lignans: chemistry, pharmacology and biotransformations. Curr Med Chem 8: 1363-1381
68. Petersen M, Alfermann AW (2001) The production of cytotoxic lignans by plant cell cultures. Appl Microbiol Biotechnol 55:135-142
69. Liu YQ, Yang L, Tian X (2007) Podophyllotoxin: Current perspectives. Curr Bioactive Compounds 3:37-66
70. You Y (2005) Podophyllotoxin derivatives: Current synthetic approaches for new anticancer agents. Curr Pharm Design 11:1695-1717
71. Malonne H, Atassi G (1997) DNA topoisomerase targeting drugs: Mechanisms of action and perspectives. Anti-Cancer Drugs 8:811-822
72. Redkar RG, Jolly CI (2003) Natural products as anticancer agents. Indian Drugs 40:619-626
73. Bohlin L, Rosén B (1996) Podophyllotoxin derivatives: Drug discovery and development. Drug Discov Today 1:343-351
74. Kuo-Hsiung L (1999) Novel antitumor agents from higher plants. Med Res Rev 19:569-596
75. Gordaliza M, Castro MA, García-Grávalos MD et al (1994) Antineoplastic and antiviral activities of podophyllotoxin related lignans. Arch Pharm (Weinheim) 327:175-179
76. Gao R, Tian X, Zhang X (2000) A brief review on podophyllotoxin analogues. Chin J Pest Sci 2:1-6
77. Zhu CG, Yang J, Li DZ (2004) Advances in antineoplasm drug-podophyllotoxin and its derivatives. Drug Evaluat 1:306-309
78. Gordaliza M, Castro MA, Miguel del Corral JM et al (2000) Synthesis and antineoplastic activity of cyclolignan aldehydes. Eur J Med Chem 35:691-698
79. Gordaliza M, Miguel del Corral JM, Castro MA et al (2001) Cytotoxic cyclolignans related to podophyllotoxin. Farmaco 56:297-304
80. Castro MA, Miguel del Corral JM, Gordaliza M et al (2004) Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin. J Med Chem 47:1214-1222
81. Kamal A, Gayatri NL, Reddy DR et al (2005) Synthesis and biological evaluation of new 4β-anilino-and 4β-imido-substituted podophyllotoxin congeners. Bioorg Med Chem 13:6218-6225
82. Zhu XK, Guan J, Tachibana Y et al (1999) Antitumor agents. 194. Synthesis and biological evaluations of 4β-mono-,-di-, and-trisubstituted aniline-4′-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles. J Med Chem 42:2441-2446
83. Lee CC, Huang TS (2001) A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G) T sites and cause telomere DNA damage. Acta Pharm Res 18:846-851
84. Suzuki S, Sakakibara N, Umezawa T, Shimada M (2002) Survey and enzymatic formation of lignans of Anthriscus sylvestris. J Wood Sci 48: 536-541
85. You JZ, Chen YZ (2000) Two new methods for synthesis of 4?-amino-4-deoxypodophyllotoxin and 4?-amino-4′-demethyl-4-deoxypodophyllotoxin. Chem J Chin 21:1064-1066
86. Tratrat C, Giorgi-Renault S, Husson HP (2002) A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives. Org Lett 4:3187-3189
87. Zhao C, Nagatsu A, Hatano K et al (2003) New lignan glycosides from Chinese medicinal plant, Sinopodophillum emodi. Chem Pharm Bull 51:255-261
88. Zhao CQ, Huang J, Nagatsu A, Ogihara Y (2001) Two new podophyllotoxin glucosides from Sinopodophyllum emodi (Wall.) Ying. Chem Pharm Bull 49:773-775
89. Gu JQ, Park EJ, Totura S et al (2002) Constituents of the twigs of Hernandia ovigera that inhibit the transformation of JB6 murine epidermal cells. J Nat Prod 65:1065-1068
90. Bathini Y, Scholte A, Kelly S et al (1999) New podophyllotoxin derivatives as potential anticancer agents: Synthesis and cytotoxicity of 4β-O-propenylpodophyllotoxin ethers. Synth Commun 29:379-385
91. Hitotsuyanagi Y, Fukuyo M, Tsuda K et al (2000) 4-Aza-2,3-dehydro-4-deoxypodophyllotoxins: Simple aza-podophyllotoxin analogues possessing potent cytotoxicity. Bioorg Med Chem Lett 10:315-317
92. Magedov IV, Manpadi M, Rozhkova E et al (2007) Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin. Bioorg Med Chem Lett 17:1381-1385
93. Magedov IV, Manpadi M, Van Slambrouck S et al (2007) Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by one-step multicomponent synthesis. J Med Chem 50:5183-5192
94. Li S-J, Zhong J-H, Wang Y-G (2006) Synthesis of new chiral N-heterocyclic carbenes from naturally occurring podophyllotoxin and their application to asymmetric allylic alkylation. Tetrahedron: Asymmetry 17:1650-1654
95. Jin Y, Chen S-W, Tian X (2006) Synthesis and biological evaluation of new spin-labeled derivatives of podophyllotoxin. Bioorg Med Chem 14:3062-3068
96. Lee N-J, Jeong I-C, Cho M-Y et al (2006) Synthesis and in vitro antitumor activity of phthalimide polymers containing podophyllotoxin. Eur Polymer J 42:3352-3359
97. Wall ME, Wani MC, Cook CE et al (1966) Plants antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890
98. Chavan SP, Pathak AB, Kalkote UR (2007) Total synthesis of (+)-camptothecin via an intramolecular palladium-catalyzed cyclization strategy. SynLett 2635
99. Hartmann JT, Lipp HP (2006) Camptothecin and podophyllotoxin derivatives: Inhibitor of topoisomerase I and II - mechanism of action, pharmacokinetics and toxicity profile. Drug Safety 29:209-230
100. Wall ME (1998) Camptothecin and taxol: Discovery to clinic. Med Res Rev 18:299-314
101. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72-79
102. Hisiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 88:3888-3890
103. Braña MF, Sanchez-Migallón A (2006) Anticancer drug discovery and pharmaceutical chemistry: A history. Clin Transl Oncol 8:717-728
104. Rothenberg ML (1997) Topoisomerase I inhibitors: Review and update. Ann Oncol 8:837-855
105. Kingsbury WD, Boehm JC, Jakas DR (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogs: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98-107
106. Sawada S, Okajima S, Piyama R et al (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate linked, water soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull 39:1446-1450
107. Potmesil M (1994) Camptothecins: From bench research to hospital wards. Cancer Res 54:1431-1439
108. García Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology and continued development of the camptothecins. Clin Cancer Res 8:641-661
109. Dennis MJ, Beijnene JH, Grochow LB, van Wamerdam LJ (1997) An overview of the clinical pharmacology of topotecan. Semin Oncol 24[1 Suppl 5]:S5-12-S5-18
110. O'Reilly S (1999) Topotecan: What dose, what schedule, what route? Clin Cancer Res 5:3-5
111. Shah C, Ready N, Perry M et al (2007) A multicenter phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 57:84-88
112. Nelson R (2007) Topotecan more effective than supportive care. Lancet Oncol 8:13
113. Spannuth WA, Leath CA, Huh WK et al (2007) A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 104: 591-595
114. Gould P (2006) Topotecan adds no benefit in advanced ovarian cancer. Lancet Oncol 7:799
115. Ormrod D, Spencer CM (2002) Topotecan in the treatment of recurrent ovarian cancer. Oncologist 7[Suppl 5]:3-18
116. Herben VMM, Ten Bokked Huinink WW, Beijnen JH (1996) Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31:85-102
117. Cersisimo RJ (1998) Irinotecan: A new antineoplastic agent for the management of colorectal cancer. Ann Pharmacother 32:1324-1333
118. Erlichman C, Sargent DJ (2004) new treatment options for colorectal cancer. N Engl J Med 351:391
119. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905
120. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335
121. Limonti A, Satta F, Pavese I et al (2003) Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805-806
122. Wasserman E, Cuvier C, Lokiec F et al (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17:1751-1759
123. Johnson IS (1968) Historical background of Vinca alkaloids research and areas of future interest. Cancer Chemother Rep 52:455-461
124. Samuelsson G (1999) Drugs of natural origin, 4th Edn. Swedish Pharmaceutical Press, Sweden
125. Effert T, Li PCH, Konkimalla VSB (2007) From traditional Chinese medicine to cancer therapy. Trends Molec Med 13:353-361
126. Xie J, Tan F (2007) Advances in studies on antitumor drugs originated from plant. Chin Trad Herbal Drugs 38:285-289
127. El-Sayed M, Velporte R (2007) Catharantus terpenoids indole alkaloids: biosynthesis and regulation. Phytochem Rev 6:277-305
128. Levêque D, Jehl F (2007) Molecular pharmacokinetics of Catharanthus (Vinca) alkaloids. J Clin Pharm 47:579-588
129. Himes RH (1991) Interactions of Catharantus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51:257-267
130. Ding YF, Bao XD, An LJ (2005) Progress research of antitumor agents vinblastine analogues. Chin J Pharm 26:424-428
131. You J, Wan F, de Cui F et al (2007) Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int J Pharm 343:270-276
132. Mano M (2006) Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer Treat Rev 32:106-118
133. Goodman J, de Walsh V (2001) The story of taxol: Nature and politics in the pursuit of an anticancer drug. Cambridge University Press, Cambridge
134. Kingston DGI, Newman DJ (2007) Taxoids: Cancer-fighting compound from nature. Curr Opin Drug Discov Dev 10:130-144
135. Yazdani D, Shahnazi S, Rezazadeh Sh, Pirali Hamadani M (2005) Review on yew tree (Taxus spp). J Medicinal Plants 4:1-8
136. Kingston DGI (2001) Taxol, a molecule for all seasons. Chem Commun 867-880
137. Nicolau KC, Yang Z, et al (1994) Total synthesis of taxol. Nature 367:630-634
138. Danishefsky SJ, Masters JJ, Young WB et al (1996) Total synthesis of baccatin III and taxol. J Am Chem Soc 118:2843-2859
139. Borah JC, Boruwa J, Barua NC (2007) Synthesis of the C-13 side-chain of taxol. Curr Org Syn 4:175-199
140. Guo BH, Kai GY, Jin HB, Tang KX (2006) Taxol synthesis. Afr J Biotechnol 5:15-20
141. Shi Q-W, Kiyota H (2005) New natural taxane diterpenoids from Taxus species since 1999. Chem Biodivers 2:1597-1623
142. Nakagawa-Goto K, Yamada K, Nakamura S et al (2007) Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant - taxoid conjugates as novel cytotoxic agents. Bioorg Med Chem Lett 17:5204-5209
143. Ferjancic Z, Matovic R, Cekovic Z et al (2006) Synthesis, biology, and modeling of a C-4 carbonyl C,D-seco-taxoid. Tetrahedron 62:8503-8514
144. Kuznetsova L, Chen J, Sun L et al (2006) Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett 16:974-977
145. Kingston DGI (2007) The shape of things to come: Structural and synthetic studies of taxol and related compounds. Phytochemistry 68:1844-1854
146. Sengupta S (2006) Drug target interaction of tubulin-binding drugs in cancer therapy. Exp Rev Anticancer Ther 6:1433-1447
147. Bergstralh DT, Ting JP-Y (2006) Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 32:166-179
148. Altmann K-H, Gertsch J (2007) Anticancer drugs from nature - natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 24:327-357
149. Leistner E (2005) Drugs from nature: Biology of taxanes. Pharm Unserer Zeit 34:98-103
150. Malonga H, Neault JF, Diamantoglou S, Tajmir-Riahi HA (2005) Taxol anticancer activity and DNA binding. Mini-Rev Med Chem 5:307-311
151. Kingston DGI, Bane S, Snyder JP (2005) The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle 4:279-289
152. Nabholtz J-M, Gligorov J (2005) The role of taxanes in the treatment of breast cancer. Exp Opin Pharmacother 6:1073-1094
153. Dubois J (2006) Recent progress in the development of docetaxel and paclitaxel analogues. Exp Opin Ther Patents 16:1481-1496
154. Fang WS, Lian XT (2005) Recent progress in structure activity relationship and mechanistic studies of taxol analogues. Mini-Rev Med Chem 5:1-12
155. Ojima I, Geney R, Ungureanu IM, Li D (2002) Medicinal chemistry and chemical biology of new generation taxane antitumor agents. IUBMB Life 53:269-274
156. Ojima I, Geng X, Wu X et al (2002) Tumor-specific novel taxoid-monoclonal antibody conjugates. J Med Chem 45:5620-5623
157. Tietze LF, Bell HP, Chandrasekhar S (2003) Natural product hybrids as new leads for drug discovery. Angew Chem Int Ed 42:3996-4028
158. White SJ, Kasman LM, Kelly MM et al (2007) Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med 43:1313-1321
159. Busquets S, Ametller E, Fuster G et al (2007) Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 245:144-148